Literature DB >> 8713088

Molecular recognition of peptide and non-peptide ligands by the extracellular domains of neurohypophysial hormone receptors.

J Howl1, M Wheatley.   

Abstract

This study was designed to ascertain whether the extracellular loops of vasopressin/oxytocin receptors bind ligands and, if so, to locate the molecular determinants of this ligand-receptor interaction. Ligand-binding studies were employed using a rat liver V1a vasopressin receptor preparation and both peptide and non-peptide receptor ligands. Synthetic peptides corresponding to defined regions of the extracellular surface of the neurohypophysial hormone receptors recognized radioligands. These receptor mimetics inhibited the binding of radioligands to the V1a receptor with apparent affinities (pKi) ranging from 3.1 to 6.75. The same mimetics had no effects on the binding of angiotensin II to the rat AT1 receptor, indicating specificity for V1a receptor ligands. A mimetic peptide (DITYRFRGPDWL) of the first extracellular loop (ECII) of the V1a vasopressin receptor also inhibited vasopressin-stimulated, but not angiotensin II-stimulated, glycogen phosphorylase in isolated rat hepatocytes. In contrast, scrambled ECII mimetics displayed greatly reduced affinity for vasopressin. In addition, the role of peptide side-chain versus main-chain atoms in the binding of ligands by vasopressin receptors was addressed using retro-inverso peptide mimetics. Our findings indicate a precise orientation of the extracellular receptor surface (particularly the ECII domain) which facilitates the initial 'capture' of both peptide and non-peptide ligands. Moreover, the data indicate that the main-chain atoms of both a major binding-site determinant in the first extracellular loop of the receptor and the neurohypophysial hormones contribute significantly to the ligand-receptor interaction. These findings also suggest that soluble receptor-binding domains have therapeutic potential.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8713088      PMCID: PMC1217525          DOI: 10.1042/bj3170577

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  39 in total

1.  Identification of a domain of ETA receptor required for ligand binding.

Authors:  M Adachi; Y Y Yang; A Trzeciak; Y Furuichi; C Miyamoto
Journal:  FEBS Lett       Date:  1992-10-19       Impact factor: 4.124

2.  Structure and expression of a human oxytocin receptor.

Authors:  T Kimura; O Tanizawa; K Mori; M J Brownstein; H Okayama
Journal:  Nature       Date:  1992-04-09       Impact factor: 49.962

3.  Peptide receptors. Stepping up the pressure.

Authors:  M Sharif; M R Hanley
Journal:  Nature       Date:  1992-05-28       Impact factor: 49.962

4.  Molecular cloning and expression of a rat V1a arginine vasopressin receptor.

Authors:  A Morel; A M O'Carroll; M J Brownstein; S J Lolait
Journal:  Nature       Date:  1992-04-09       Impact factor: 49.962

5.  Purification of hepatocyte couplets by centrifugal elutriation.

Authors:  J C Wilton; D E Williams; A J Strain; R A Parslow; J K Chipman; R Coleman
Journal:  Hepatology       Date:  1991-07       Impact factor: 17.425

6.  The binding site of neuropeptide vasopressin V1a receptor. Evidence for a major localization within transmembrane regions.

Authors:  B Mouillac; B Chini; M N Balestre; J Elands; S Trumpp-Kallmeyer; J Hoflack; M Hibert; S Jard; C Barberis
Journal:  J Biol Chem       Date:  1995-10-27       Impact factor: 5.157

7.  Identification of hormone-binding regions of the luteinizing hormone/human chorionic gonadotropin receptor using synthetic peptides.

Authors:  P C Roche; R J Ryan; D J McCormick
Journal:  Endocrinology       Date:  1992-07       Impact factor: 4.736

8.  Cloning and characterization of a vasopressin V2 receptor and possible link to nephrogenic diabetes insipidus.

Authors:  S J Lolait; A M O'Carroll; O W McBride; M Konig; A Morel; M J Brownstein
Journal:  Nature       Date:  1992-05-28       Impact factor: 49.962

9.  Molecular cloning of the receptor for human antidiuretic hormone.

Authors:  M Birnbaumer; A Seibold; S Gilbert; M Ishido; C Barberis; A Antaramian; P Brabet; W Rosenthal
Journal:  Nature       Date:  1992-05-28       Impact factor: 49.962

Review 10.  Cell receptors as drugs. Ligand binding domains of receptors as drugs: a potential new class of therapeutic agents.

Authors:  G G Yarbrough; D P Taylor
Journal:  J R Coll Physicians Lond       Date:  1991-10
View more
  5 in total

1.  Designing human m1 muscarinic receptor-targeted hydrophobic eigenmode matched peptides as functional modulators.

Authors:  Karen A Selz; Arnold J Mandell; Michael F Shlesinger; Vani Arcuragi; Michael J Owens
Journal:  Biophys J       Date:  2004-03       Impact factor: 4.033

Review 2.  Lifting the lid on GPCRs: the role of extracellular loops.

Authors:  M Wheatley; D Wootten; M T Conner; J Simms; R Kendrick; R T Logan; D R Poyner; J Barwell
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

3.  Identification of the glycosylation sites utilized on the V1a vasopressin receptor and assessment of their role in receptor signalling and expression.

Authors:  S R Hawtin; A R Davies; G Matthews; M Wheatley
Journal:  Biochem J       Date:  2001-07-01       Impact factor: 3.857

4.  Novel strategies for the design of receptor-selective vasopressin analogues: Aib-substitution and retro-inverso transformation.

Authors:  J Howl; Z Prochazka; M Wheatley; J Slaninová
Journal:  Br J Pharmacol       Date:  1999-10       Impact factor: 8.739

5.  Intracellular translocation and differential accumulation of cell-penetrating peptides in bovine spermatozoa: evaluation of efficient delivery vectors that do not compromise human sperm motility.

Authors:  Sarah Jones; Monika Lukanowska; Julia Suhorutsenko; Senga Oxenham; Christopher Barratt; Steven Publicover; Dana Maria Copolovici; Ülo Langel; John Howl
Journal:  Hum Reprod       Date:  2013-04-12       Impact factor: 6.918

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.